Back to mobile site

Goldman Sachs Starts Annexon Biosciences (ANNX) at Neutral

May 12, 2026 5:15 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter initiates coverage on Annexon Biosciences (NASDAQ: ANNX) with a Neutral rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login